Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | 5.71% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.8 | ||
| Price to Tang. Book | 1.8 | ||
| Price to Free Cashflow | 13.78 | ||
| Price to Sales | 3.09 | ||
| EV to EBITDA | 4.58 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 21.25% | ||
| Return on Equity | 18.03% | ||
| Operating Margin | 38.51% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 13,137.32 | 17,581.83 | 10,989.74 | 11,429 | 11,260 | n/a | n/a | 21.77% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +1443.77 | +65.74 | -51.85 | -0.03 | -9.15 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mizuho Medy Co Ltd is a Japan-based company mainly engaged in the in vitro diagnostic pharmaceuticals business. Its market sectors include hospitals & general practitioners, and over the counter (OTC) & others. The hospitals & general practitioners sector manufactures and sells infectious disease immunoassays to medical institutions both in Japan and overseas to assess patients' health conditions, the presence or absence of diseases, and treatment progress. Its main products include immunological diagnostic reagents for infectious diseases point of care testing (POCT), urine and fecal testing reagents, and genetic testing reagents POCT. The OTC & others sector sells over the counter medicines and ovulation test kits to pharmacies and drug stores and sells fruit tree virus test kits that apply infectious disease immunoassay technology to agricultural experiment stations and other organizations to detect viral diseases in crop seedlings.
Directors
- Fuminari Karakawa CHM (73)
- Masashi Imamura MDR (62)
- Toshio Kambara DSL (57)
- Hiroshi Sasaki OTH (59)
- Kazuhiro Ichimaru OTH (61)
- Kenji Narahara OTH (58)
- Shinichi Akiyama IND (76)
- Katsumi Sasaki IND (76)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- November 2nd, 1977
- Public Since
- December 17th, 2015
- No. of Shareholders
- 18,467
- No. of Employees
- 193
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Tokyo Stock Exchange- Shares in Issue
- 19,048,650
- Address
- 5-4, Fujinoki-machi, TOSU-SHI, 841-0048
- Web
- https://www.mizuho-m.co.jp/
- Phone
- +81 942850303
- Auditors
- Deloitte Touche Tohmatsu LLC
Latest News for 4595
Upcoming Events for 4595
Q3 2026 Mizuho Medy Co Ltd Earnings Release
Dividend For 4595.T - 50.0000 JPY
Similar to 4595
Alfresa Holdings
Tokyo Stock Exchange
ASAHI INTECC
Tokyo Stock Exchange
Aso International
Tokyo Stock Exchange
As One
Tokyo Stock Exchange
Atect
Tokyo Stock Exchange
FAQ
As of Today at 04:08 UTC, shares in Mizuho Medy are trading at ¥1,752. This share price information is delayed by 15 minutes.
Shares in Mizuho Medy last closed at ¥1,752 and the price had moved by +7.16% over the past 365 days. In terms of relative price strength the Mizuho Medy share price has underperformed the Nikkei 225 Index by -20.81% over the past year.
The overall consensus recommendation for Mizuho Medy is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Mizuho Medy dividend yield is 5.71% based on the trailing twelve month period.
Last year, Mizuho Medy paid a total dividend of ¥100, and it currently has a trailing dividend yield of 5.71%.Looking ahead, shares in Mizuho Medy are due to go ex-dividend on 2026-12-29 and the next dividend pay date is 2027-03-30.
Mizuho Medy are due to go ex-dividend on 2026-12-29 and the next dividend pay date is 2027-03-30. The historic dividend yield on Mizuho Medy shares is currently 5.71%.
To buy shares in Mizuho Medy you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥1,752, shares in Mizuho Medy had a market capitalisation of ¥33bn.
Here are the trading details for Mizuho Medy:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4595
Based on an overall assessment of its quality, value and momentum Mizuho Medy is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Mizuho Medy is ¥1,700. That is 2.97% below the last closing price of ¥1,752.
Analysts covering Mizuho Medy currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mizuho Medy. Over the past six months, its share price has underperformed the Nikkei 225 Index by -13.36%.
As of the last closing price of ¥1,752, shares in Mizuho Medy were trading +0.25% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Mizuho Medy PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥1,752.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Mizuho Medy's management team is headed by:
- Fuminari Karakawa - CHM
- Masashi Imamura - MDR
- Toshio Kambara - DSL
- Hiroshi Sasaki - OTH
- Kazuhiro Ichimaru - OTH
- Kenji Narahara - OTH
- Shinichi Akiyama - IND
- Katsumi Sasaki - IND